Entrada Therapeutics announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately. Sethuraman joined Entrada Therapeutics as Chief Scientific Officer in 2017
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
- Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
- Entrada Therapeutics Reports Second Quarter 2024 Financial Results
- Entrada Therapeutics reports Q2 EPS $1.55, consensus 14c